|Articles|April 20, 2020

Monitoring Product Quality Attributes of Biotherapeutics at the Peptide Level Using the Agilent InfinityLab LC/MSD XT System

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Monitoring Product Quality Attributes of Biotherapeutics at the Peptide Level Using the Agilent InfinityLab LC/MSD XT System

Newsletter

Related Content

Particle Risk Mitigation in Biomanucturing

Executive Summary: Charge Detection Mass Spectrometry (CDMS): From Complexity to Clarity – A New Era in Biomolecular Analysis

Executive Summary: Supporting mRNA Development With Quantitative Expression Analysis

Applying Analytical Quality by Design Principles to Biopharma Method Development and Optimization

Executive Summary: Mastering Nitrosamines Analysis With Streamlined LC-MS/MS Solutions

Trending on BioPharm International

Top 10 Questions from CPHI Frankfurt: Building Pharma Resilience a Common Theme

Distribution Resilience: Meeting Global Demand and Delivering Faster, More Reliable Service

Scaling Manufacturing of Novel Therapies

2025 PharmSci 360 to Showcase Essential AI Integration and Emerging Technologies

Streamlining Procurement and Inventory Management Leads to Increased Productivity